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Lung cancer remains the leading cause of cancer death. Understanding lung tumors physiopathology should provide opportunity
to prevent tumor development or/and improve their therapeutic management. Cancer stem cell (CSC) theory refers to a
subpopulation of cancer cells, also named tumor-initiating cells, that can drive cancer development. Cells presenting these
characteristics have been identiﬁed and isolated from lung cancer. Exploring cell markers and signaling pathways speciﬁc to lung
CSCs may lead to progress in therapy and improve the prognosis of patients with lung cancer. Continuous eﬀorts in developing in
vitro and in vivo models may yield reliable tools to better understand CSC abilities and to test new therapeutic targets. Preclinical
data on putative CSC targets are emerging by now. These preliminary studies are critical for the next generation of lung cancer
therapies.
1.Introduction
Despite important improvements in therapies over the
last decades, lung cancer prognosis remains very poor.
After apparent successful initial therapy, development of
secondary tumors often leads to a lethal relapse. Substantial
growing experimental evidence has suggested that many
cancers, including lung cancer, may be driven by a small
subpopulation of self-renewing cells that could sustain
malignant growth [1]. Innovative therapy could target this
speciﬁc population of “cancer stem cells” (CSCs) or “tumor-
initiating cells” in order to improve patients’ outcome,
with complete eradication of tumor growth. This review
summarizes what is known about lung CSCs and focuses
on potential clinical implications based on preclinical data
obtained through new in vitro and in vivo models.
2. Cancer Stem Cells
Two major models have been described for tumor propa-
gation: the clonal evolution model, involving a stochastic
component, and the CSC model deﬁned as hierarchical.
According to the clonal evolution model, neoplasm arise
from a single cell of origin, and tumor progression results
from acquired genetic variability within the original clone
allowing sequential selection of more aggressive sublines [2].
CSC model sustains that tumor cells are heterogeneous and
only the CSC subset has the ability to proliferate extensively
and form new tumors [1, 3]. These models are not mutually
exclusive [4]. Recent data provide support for the CSC
hypothesis, which suggests that a relatively rare subpopula-
tion of tumor cells have the unique ability to initiate and
perpetuate tumor growth [5]. CSCs have been identiﬁed and
isolated in various malignancies including solid tumors [6–
10]s u c ha sl u n gc a n c e r[ 11]. These cells can be deﬁned as
cancer cells that speciﬁcally possess the ability to give rise to
all cell types found in a particular cancer sample. CSCs share
various characteristics with embryonic and somatic stem
cells including self-renewal and multipotent diﬀerentiation
[12, 13]. Self-renewal is deﬁned as the ability to go through
unlimited cycles of cell division while maintaining the
undiﬀerentiated state. Stem cells are characterized by the
capacity to renew themselves through mitotic cell division
and diﬀerentiate into a diverse range of specialized cell2 Journal of Oncology
types. Indeed, self-renewal, which drives tumorigenesis, and
diﬀerentiation albeit aberrant that contributes to cellular
heterogeneity of the tumor, are considered the key properties
of the CSC.
Stem cell populations are established in niches, which
are deﬁned as speciﬁc locations that regulate how these cells
participate in tissue regeneration, maintenance, and repair
[14]. The stem cell niche represents the microenvironment
that interacts with stem cells to regulate stem cell self-
renewal and diﬀerentiation. The dependence of normal stem
cells on the niche limits their expansion. CSCs might arise
from normal stem cells that have acquired mutations that
enable them to escape from niche control [15]. There is
increasing evidence of the importance of the tumor and the
host microenvironment in conditioning the stem cell status
itself [16]. The expansion of the niche cells may be driven by
alterations in the CSCs or in the niche cells themselves. In
either case, there is an expansion of the self-renewing CSC
pool that gives rise to aberrantly diﬀerentiated cancer cells,
which comprise the bulk of the tumor [17]. Alterations in
CSCsmayenablethemtocommandeeralternativenichecells
to provide them with self-renewal signals. Vascular niche
in brain tumors has been shown to contribute directly to
the generation of CSCs and tumor growth [18]. Although
some stem cells are perivascular, others may occupy hypoxic
niches and be regulated by O2 gradients [19]. However, the
underlying mechanisms remain unclear. O2 availability may
have a direct role in stem cell regulation through HIF-1α
modulationofWnt/β-cateninsignaling[20].IfCSCsdepend
upon aberrant niche microenvironments, then these niches
might represent targets for treatments.
Some fundamental characteristics are needed to rec-
ognize CSCs. The term CSC is frequently referred to as
“cancer initiating cells”, since serial transplantation of CSCs
into animal models re-establishes part of the phenotypic
heterogeneity of the primary tumor [21]. Xenotransplan-
tation in immunocompromised mice, followed by serial
transplantation, is now regarded as an essential criterion
in deﬁning CSCs. This preponderant characteristic might
represent the mechanistic parallel of regenerating a tissue or
a no r g a ni nn o r m a ls t e mc e l l .T h e s ec e l l sc a nb eg r o w nin
vitro as tumor spheres under nonadherent conditions [22].
Self-renewal capacity also has to be documented.
CSCs have been shown in in vitro models to be highly
resistant to radiation [23] and chemotherapy [24], poten-
tially resulting in residual disease that can lead to recurrence.
However, radioresistance of CSCs remains controversial.
Inconsistent experimental results could be related to diﬃ-
culty in correctly isolating the CSC subpopulation within
at u m o r[ 25]. CSCs may be less vulnerable to treatments
because of intrinsic properties of radio and chemoresistance
[26]. One hypothesis is that CSCs could be more resistant
to DNA damages induced by these treatments [27, 28]. They
may have enhanced capacities of DNA repair [29].
The frequency of CSCs appears to be highly variable,
reﬂecting biological diversity among cancer models as well
as technical issues. This subpopulation of cells was identiﬁed
utilizing ﬂow-cytometer-based cell sorting, enabling isola-
tion of a “side population” (SP) deﬁned by Hoechst 33342
dye exclusion [30]. This test is based on ABCG2 transporter,
which is the second member of the G subfamily of ATP
binding cassette (ABC) transporters. ABCG2 is one of the
most important multidrug-resistance transporters and its
substrates include Hoeschst 33342 [31]. This transporter is
highly expressed in the SP containing stem cells [32]. CSCs
are capable of self-renewal and production of diﬀerentiated
progenitors. Progenitors are engaged in a diﬀerentiation
pathway that progressively generates the diﬀerent mature
cells. CSCs express tissue-speciﬁc cell surface markers, such
as CD34 in several kinds of leukemia [33] and CD44 in
breast cancer [6]. None of these markers are speciﬁc to
CSCs: CD34 is expressed by endothelial and hematologic
normal cells, while CD44 is expressed by endothelial and
mesenchymal cells. CD133 has been observed in a wide
spectrum of malignant tumors including lung cancer [11,
34]. The function of CD133 is still unknown. CD133 may
have a role in stem cell activation/maintenance [35], and
potential regulatory activity of cell-cell contacts [36]. The
CSC phenotype may not necessarily be uniform between
cancer subtypes or even tumors of the same subtype [37].
Aldehyde dehydrogenase (ALDH) metabolizes a wide variety
of endogenous and exogenous aldehydes [38]. High ALDH
activity has been detected in stem and progenitor cells
in various lineages [39–41], suggesting that strong ALDH
activity and/or antigen expression can be used as a marker
for CSC in a variety of cancers, including lung cancer [42].
3.DoestheCancerStemCellConcept
Remain Disputed?
In the stochastic model, transformation results from a
random mutation and subsequent clonal selection. But
this model may not be suﬃcient to fully explain biology
of carcinogenesis. The conceptual gap left by this model
could be ﬁlled in by CSC hypothesis which becomes very
attractive in this context. Indeed carcinogenesis involves
acquisition and accumulation of genetic mutations and
epigenetic regulations that may take many years. Since the
normal lung epithelium turns over fairly rapidly, there
must be some very long-lived cell type that serves as the
repository to safeguard all these accumulating mutations.
This can ﬁt with CSC hypothesis and therefore explain
both heterogeneity of cancer cells and events of metastasis.
This theory may bring fundamental bases for understanding
resistance to chemotherapy or radiation treatment, tumor
promotion and progression, as well as important clinical
implications for detection, prevention, and treatment [3].
However, some controversies still remain [43–45]. Tumor
growth may not need to be driven by rare cancer stem cells.
Cancer stem cell theory may not be an absolute requisite to
explain chemo-radio resistance. This characteristic may be
related to multiple drug resistance (mdr) phenotype [46].
Metabolicﬂexibilitymaygenerateadaptivechangesincellsof
the residual disease that can lead to tumor growth [47]a n d
relapse. Tumor progression and recurrence may be explained
by a state of cancer dormancy [48]. CSC may not be a
real entity. CSC theory could be the simple transpositionJournal of Oncology 3
of normal tissue development to cancer. Although the CSC
hypothesis still has to be fully validated in lung cancer,
its applicability would provide an improvement in our
understanding of carcinogenesis.
4. LungCancer
Lung cancer is one of the most intractable cancers with a
ﬁve-year overall survival of around 15% all stages merged.
Lung cancer has a poor prognosis, because of extra thoracic
dissemination and frequent disease relapse. The main types
of lung cancer are small cell lung carcinoma SCLC and
nonsmall cell lung carcinoma NSCLC, which includes three
major histological types: adenocarcinoma, squamous cell
carcinoma (SCC), and large cell carcinoma [49]. About 15%
of the tumors are SCLCs and arise in the larger airways, grow
rapidly, and have a neuroendocrine component. Adenocarci-
nomas represent about 40% of NSCLCs and usually start in
peripherallungtissue.SCCs accountfor25%andcommonly
originate near a central bronchus. Large cell carcinomas
are believed to derive from neuroendocrine cells and may
be observed in combination with other types of NSCLC.
These neuroendocrine lung tumors appear to be epithelial
tumors characterized by their preferential neuroendocrine
diﬀerentiation as indicated by neuroendocrines granules,
mucin granules, microvilli, and tonoﬁlaments [50].
It is estimated that smoking causes 90% of lung cancers.
However, diﬀerent types of genetic modiﬁcations have been
described in lung cancer cells such as recurrent chromosome
abnormalities [51], upregulation of telomerase activity [52],
and mutations of oncogenes or tumor suppressor genes
(TP53,RB1,CDKN2A,KRAS,EGFR).Somemaybemarkers
of disease progression, others may have a direct role in
lung cancer genesis in the context of gene-environment
interactions [53]. The link between mutations and stem cell-
ness is an important issue that needs to be explored. It is
not clear whether mutations leading to CSCs occur in stem
cells or in diﬀerentiated cells. These data strongly suggest
that a deep knowledge of each tumor should improve patient
outcome thanks to personalized therapy.
5. Normal Lung Stem Cells
The respiratory system arises from the ventral foregut endo-
derm with development of a tree-like system of epithelial
tubulesandvascularstructures,whichultimatelygivesriseto
the mature airways and alveoli. Precise sequence and pattern
of branching events lead to highly ramiﬁed tubular networks
possibly driven by a stereotyped hierarchical and modular
branchingprogram[54]whichmolecularregulationremains
under study [55]. Lung mesenchymal development is cru-
cially inﬂuenced by signals from the epithelium and the
pleurathat,inconcert,appeartomaintainabalanceofdiﬀer-
entiated and proliferating multipotent progenitors while the
lung grows [56]. During lung branching morphogenesis, the
transcription factor Sox2 is associated with the epithelium
t h a ti sl e s sm o r p h o g e n e t i c a l l ya c t i v e .Sox2 expression is lost
at sites where nascent buds arise [57, 58]. As epithelial cells
in branching airways continue to diﬀerentiate, it is crucial
to maintain and expand a pool of uncommitted progenitor
cells for continuous growth. It has been proposed that this
poolresidesinthedistallung,asapopulationofproliferating
immature epithelial cells that expresses high levels of the
proto-oncogene Mycn [59].
Mature respiratory epithelium consists of multiple cell
types. Ciliated, neuroendocrine, and secretory cells are
located in the proximal region of the respiratory system.
Alveolar type 1 (AT1) and 2 (AT2) cells are typical of the
distal alveolar region of the lung (Figure 1). Lineage analysis
suggests that progenitor cells lining the trachea and proximal
lung have a diﬀerent origin from those lining the distal
region of the lung [60]. The activity of the diﬀerent pools
of progenitor cells account for spatially restricted regional
speciﬁcities in both proximal and distal cell lineages speci-
ﬁcations during lung development and cellular composition
of tracheobronchial and bronchiolar airways [61]. Basal
cells have been proposed as a multipotent progenitor cell
population of bronchial airways. They have the capacity
for restoration of a fully diﬀerentiated epithelium [62, 63].
Lung CSCs and airway normal stem cells may use common
pathways in development.
6. LungCancer Stem Cells
Alteredcompositionofairwayepithelialcellthatisassociated
with acute or chronic lung injury has the potential to
signiﬁcantly increase risk for developing lung cancer [64,
65]. It is currently unknown whether airway stem cells
contribute signiﬁcantly to normal epithelial maintenance
and repair [66]. Clara cells participate in maintenance of
both secretory and ciliated cell types after oxidant-mediated
damage [67]. Meanwhile a population of pollutant-resistant
stem cells localized in the bronchoalveolar duct junction
(BADJ)contributestorestorationofaphenotypicallydiverse
epithelium after clara cell depletion [68]. These cells are
named bronchoalveolar stem cells (BASCs) (Figure 1). Both
pulmonary neuroendocrine cells (PNEC) and Clara cells
have been proposed as progenitors for the genesis of SCLC
and NSCLC [69].PNECarespecializedairwayepithelial cells
that produce speciﬁc neuropeptides and that are grouped
in clusters termed neuroepithelial bodies (NEBs). Repair
from airway injury is associated with PNEC hyperplasia
[70]. Cells with Clara-like characteristics but reduced secre-
tory protein expression have been identiﬁed in association
with preneoplastic lesions [71]. These data suggest that
cells engaged in diﬀerentiation could reactivate genes of
immaturity. In this context, CSCs may arise from restricted
progenitors or more diﬀerentiated cells that have reacquired
self-renewing capacity [5]. This phenomenon could have
direct bearing on the issue of stem cell plasticity, which is
deﬁned as the ability to cross lineage barriers and adopt cell-
diﬀerentiated phenotypes [72]. It also may raise a parallel
with transdiﬀerentiation from diﬀerentiated cell to CSC that
leads to cancer cell phenotypic diversiﬁcation [73]. BASCs at
theBADJofadultairwayshavebeenproposedasaninitiating
cell source for lung adenocarcinoma [74]. Stem cells and4 Journal of Oncology
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Figure 1: Lung CSCs and progenitors which diﬀerentiation leads to heterogeneity of associated human carcinomas. Normal and tumor
cellular hierarchy progressively generates progenitor cells and diﬀerentiated mature cells in both proximal and distal airways. Hypotheses are
represented with discontinuous lines.
progenitorscouldbeconsideredidealtumorinitiatingcandi-
dates,becausedysregulationofproliferativecapacitythrough
mutation may rapidly cause dysplastic tumor-like growth.
The deviation from a common endodermic stem cell could
also be responsible for the multidirectional diﬀerentiation
in lung tumors, including neuroendocrine phenotype in
NSCLC and squamous or glandular signs of diﬀerentiation
in authenticated neuroendocrine tumors [75].
Observed phenotypic heterogeneity between distinct
tumor types suggests that the tumor’s local pulmonary
environment deeply impacts the fate of cancer cells [76].
Developmental programs of cells initially engaged in a
speciﬁc lineage pathway can be altered by changing the type
of signals in the local environment [77]. The diﬀerent lung
tumors could arise from regiospeciﬁc cancer stem cell niches
that are still debated [78, 79].Journal of Oncology 5
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7. LungCancer Stem CellModels
Tumorigenic human lung cancer cells have been isolated
using diﬀerent approaches from both cell lines and primary
tumors. CSC models from lung cancer cell lines are based
on the phenotype or on the functional characteristics of
these cells (Figure 2). SP has showed repopulating ability
and resistance to multiple chemotherapeutic drugs in lung
cancer. In addition, human telomerase reverse transcriptase
(hTERT) expression is higher in SP, suggesting that this
fraction may represent an enriched source of lung tumor
initiating cells with unlimited proliferative potential [80–
83]. CSCs can be identiﬁed and isolated by ﬂow-cytometry-
based cell sorting using the cell surface marker CD133 [37]
(Figure 2). The lack of early markers for lung progenitors
represents a clear gap of knowledge. The known markers
are not always ideal to sort for the CSC population [84].
In line with tumor heterogeneity, the phenotype of CSCs is
not uniform, underlying the necessity to ﬁnd more speciﬁc
single markers or to deﬁne new marker combinations to
potentially recognize the putative CSCs (Table 1). Isolation
of lung CSCs based on increased ALDH activity was
obtained using the Aldeﬂuor assay followed by ﬂuorescent-
activated cell sorting (FACS) (Figure 2)[ 42, 85]. The second
approach leading to the isolation of lung CSCs was based
on their inherent functional resistance to chemotherapy
(Figure 2). Drug-surviving cells were isolated after an in
vitro treatment with cisplatin, doxorubicin, or etoposide.
These cells present the phenotypic characteristics previously
described [86]. These diﬀerent CSC models developed on
cancercelllinescanbegrowninvitroastumorspheresunder
nonadherent conditions using a serum-free medium that is
supplemented with growth factors. They also exhibit high
clonogenic potential, capacities for self-renewal, generation
of diﬀerentiated progeny, and high in vivo tumorigenicity
(Figure 3).
The ﬁrst isolation and expansion of lung CSCs from
primary patient tumors was based on their ability to survive
under serum-free conditions and proliferate as cellular
tumor spheres [11]. CD133 cells isolated from primary
tumors displayed features of CSCs both in vitro and in
vivo [87, 88]. The expression of CD133 in tumors was
linked to shorter progression-free survival in patients treated
with platinum-based chemotherapies, but this point remains
controversial [88–91].
In vivo limiting dilution consists of injection of decreas-
ing number of cells. This method used for subcutaneous
tumor xenograft may prove enrichment of CSCs in an
isolated subpopulation of cells [27, 92]( r a t i ot oo b t a i na
tumor from CSCs compared to tumor cells: 1/100). To date,
there is no consistent data published on this method in lung
CSC models that determine the minimal number of tumor-
initiating cells necessary and suﬃcient to regenerate a tumor.
A few mouse models of lung cancer-initiating cells have
been developed [74, 93]. However the frequency of CSCs in
these models is highly variable. To date, there is no evidence
of a subpopulation isolated from an animal model able to
restore the tumor initial heterogeneity in secondary and
tertiary hosts [84].
8.PreclinicalDataon LungCancerStemCells
The surviving fraction of tumor cells after chemotherapy
is low and may contain CSCs. These cells “left behind”
may be responsible for recurrence. These cells need to
be eradicated in order to provide long-term disease-free
survival. Combinatorial treatments involving both cytotoxic
and targeted therapies will probably be required to suppress
all cancer cells [5]. Preclinical data on putative CSCs targets
are emerging by now.
Oncogenes and tumor-suppressor genes are the 2 types
ofgenesinvolvedincarcinogenesis.Oncogenesaredominant
genes [94] whereas tumor suppressor genes are recessive.
Activating mutations or transcriptional deregulation can
lead from proto-oncogenes to oncogenes. The Runx genes
can present characteristics of both oncogenes and tumor
suppressor genes. These genes encode transcription factors
involved in normal development with tissue speciﬁc expres-
sion. Many chromosomal translocations involving Runx
genes and leading to oncogenic fusion proteins have been
reported [95]. These fusion proteins may have a tissue-
restricted oncogenic spectrum [96] in accordance with the
concept of lineage-speciﬁc oncogenes. This concept applied
to CSCs could suggest that some speciﬁc oncogenes could
select and maintain a particular malignant phenotype char-
acteristic of a cell lineage. Runx3 is an essential transcription
factor for the late phase of lung development. Runx3 is
required for the control of diﬀerentiation and proliferation
of bronchiolar epithelium [97]. The frequent silencing of
Runx3 by promoter hypermethylation in the preneoplastic
stageofthelungadenocarcinomahasbeenobserved[98,99].
Runx3 downregulation has been proposed as an early event
in the development of the lung carcinoma interfering in the
diﬀerentiation of progenitor cells [97]. Moreover, there are
some data suggesting that in lung cancer TITF1 could be an
adenocarcinoma lineage speciﬁc oncogene [100]a n dBRF2 a
squamous cell lineage speciﬁc oncogene [101].
BASC possesses the potential to diﬀerentiate into Clara
or AT2 cells, presenting coexpression of Clara cell secretory
protein (CCSP) and surfactant protein C (SPC) (Figure 1)
[74]. These cells also exhibit the capacity of self-renewal and
the expression of Oct4. Oct4 is a transcriptional factor of
the embryonic stem cells which expression was found to be
associated with a poor prognosis [87, 102, 103]. In addition,
knock down of Oct4 might lead to apoptosis of a CSC-like
population of lung cancer cells [104].
Sox2 is a critical transcription regulator of embryonic
stem cells [105]. Sox2 controls self-renewal and diﬀer-
entiation processes [106]. It is also implicated in lung
branching morphogenesis during pulmonary development
as previously evocated [57, 58]. Sox2 has been proposed
to be an oncogene which expression is essential to lung
SCC carcinogenesis and which is capable of transforming
and conferring tumor initiating properties to human lung
squamous cells [107]. Additionally, tumors with Sox2 over-
expression seem to have a worse prognosis [108].
Oct4 and Sox2 are two of the four crucial transcription
factors capable of cooperating to reprogram diﬀerentiated
cells into an induced pluripotent stem cell-like phenotypeJournal of Oncology 7
Table 1: Molecular characterization of putative human lung CSCs.
Molecular characterization References
Surface markers and transporters:
CD133 [11, 34, 37, 87–91]
Side population—ABCG2 [80–83, 91]
ALDH activity [42, 85]
Transcription factors:
Runx3 [97–99]
Sox2 [107, 108]
Oct4 [87, 102–104]
c-kit [111, 115]
[109, 110]. Nuclear transplantation of Oct4, Sox2, c-Myc,
and Klf4 can reprogram a somatic genome back into an
embryonic stem cell status. Is there a comparable way for
cancer cells to reacquire an immature proﬁle with properties
of self-renewal? Oct4 and Sox2 may participate to a similar
process leading to lung CSCs.
Stem Cell Factor (SCF) is a mitogenic and angiogenic
factor involved in carcinogenesis. Human c-kit has been
shown to operate as a SCF receptor promoting tumor growth
[111–113]. Patients with either mutation or overexpression
of c-kit have lower survival rates and show resistance to
chemotherapy [114]. Blocking SCF/c-kit signaling pathway
inhibits CSC proliferation and survival after chemotherapy
exposure in human lung cancer cell lines [115]. Exposure
to SCF/c-kit axis blockade by SCF-neutralizing antibodies
or by imatinib (Gleevec), an inhibitor of c-kit, combined to
cisplatin therapy might lead to inhibition of both non-CSCs
and CSCs.
Diﬀerences between normal stem cells and CSCs may
provide novel antigenic and molecular targets for ther-
apy (Table 1). It is important to design new therapeutic
approaches to selectively hit CSC-speciﬁc pathways, while
sparing normal stem cells. Further identiﬁcation of lung
cancer stem cell-speciﬁcs target could allow for promising
more eﬀective combined therapies. In our view, the most
important matter to address in a near future is to better
characterize and isolate lung CSCs from patients’ tumors
combining marker studies and functional assays. Lung CSCs
probably include a heterogeneous population of cells with
diﬀerent therapeutic resistance proﬁles. Identifying lineage
speciﬁc oncogenes or their fusion proteins could bring new
targets for speciﬁc therapeutic approaches selectively aimed
at speciﬁc CSCs. In contrast to chemotherapy or radiother-
apy on mature tumor cells, therapies against CSCs might
have a slow but sustainable eﬀect. Therefore experimental
models will certainly have to be redrawn including longer
observation periods and intermediate analysis.
9. Conclusion
CSC is central to cancer cell biology and cancer therapy.
The knowledge of CSC signaling pathways may lead to new
therapies able to eradicate lung CSC or induce diﬀerenti-
ation of these cells. Promising models have recently been
developed to isolate the subpopulation of CSCs within the
lung-diﬀerentiated cells of the tumor mass. These models
are useful tools to better characterize lung CSCs. Targeting
the CSC or its microenvironmental niche could inhibit
self-renewing and overcome chemo-radio resistance. Some
consistent preclinical data are emerging on the role of
transcriptional factors such as Runx3, Oct4, Sox2,a n dc-
kit in lung tumor diﬀerentiation and treatment resistance.
Further in vitro and in vivo studies are needed to design
combined therapies in order to determine whether these
candidatesarepotentialtargetsfornewtherapeuticstrategies
against lung cancer. Moreover, the prognostic and predictive
value of CSCs identiﬁcation from tumor biopsies or among
circulating tumor cells remains to be determined.
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